Board has approved preferential allotment in meeting dated 11 July 2026
FUNDRAISE
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 11 Jul 2026, 02:53 PM IST · BSE ID: d3409103-cd79-4b8d-9b57-16baf99eac82
View Original BSE Filing (PDF)
💡
In Simple Terms
Arvaya Healthcare will buy a gastroenterology institute by issuing new shares and plans to raise Rs. 210 Cr through a rights issue.
🤖 AI Summary
- Board approves acquisition of Sushodha Institute of Gastroenterology for Rs. 15,48,74,160.
- Company to issue up to 38,71,854 equity shares at Rs. 40 per share for the acquisition.
- Up to Rs. 210 Crores fundraise approved via Rights Issue to eligible equity shareholders.
- Rights Issue Committee formed to manage terms and conditions for the upcoming Rights Issue.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Consideration
Rs. 15,48,74,160/-
Shares to be issued for acquisition
38,71,854
Issue Price per share for acquisition
Rs. 40/-
Maximum Rights Issue Amount
Rs. 210 Crores
🏢 How This Affects the Company
The acquisition expands Arvaya Healthcare's presence in the gastroenterology sector. The planned rights issue aims to fund growth initiatives and potentially improve the company's capital structure.
The acquisition consideration of Rs. 15,48,74,160 will be discharged through equity shares, diluting existing shareholders. The Rs. 210 Crores rights issue will increase equity capital.
Integration of Sushodha Institute of Gastroenterology will be required. The formation of a Rights Issue Committee signifies active preparation for fundraising.
The company undertakes new debt/equity raising activities which carry execution and market risks. Shareholder approval is required for these transactions.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Shareholders will have the opportunity to participate in the upcoming Rights Issue.
👤
Who Is Affected
All equity shareholders are affected due to potential dilution from the preferential issue and participation rights in the rights issue.
🔍
Management Signal
Management is pursuing strategic acquisition and capital infusion to expand operations and fund growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder approval for preferential allotment and rights issue.
Record date and terms for the Rs. 210 Crores Rights Issue.
Completion status of Sushodha Institute of Gastroenterology acquisition.
MEDIUM RISK
Acquisition and large rights issue require shareholder and regulatory approvals, and market acceptance.
💡 Investor Takeaway
Arvaya Healthcare will acquire Sushodha Institute for Rs. 15.49 Crore via share allotment and plans a Rs. 210 Crore rights issue. A Rights Issue Committee has been formed.
⚖️ Strengths & Concerns
✅ Positives
- Board approves acquisition of 100% of Sushodha Institute of Gastroenterology for Rs. 15,48,74,160.
- Company plans to raise up to Rs. 210 Crores via Rights Issue for future growth.
⚠️ Concerns
- Acquisition consideration of Rs. 15,48,74,160 to be paid via equity shares, leading to dilution.
- Rights Issue of up to Rs. 210 Crores requires market conditions and shareholder approvals.
📅 Company Track Record
The company was formerly known as Bijoy Hans Limited. In a prior filing on July 11, 2026, Arvaya Healthcare announced plans for a Rs. 210 Cr Rights Issue and this acquisition.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the total value of the acquisition approved by Arvaya Healthcare?
Arvaya Healthcare approved the acquisition of 100% equity shares of Sushodha Institute of Gastroenterology Private Limited for a total purchase consideration of Rs. 15,48,74,160/-.
How will Arvaya Healthcare pay for the acquisition of Sushodha Institute?
The purchase consideration will be discharged by issuing up to 38,71,854 fully paid-up equity shares of the Company at a price of Rs. 40/- per equity share.
What is the maximum amount Arvaya Healthcare plans to raise through its Rights Issue?
The Board of Directors approved fundraising by way of a Rights Issue of Specified Securities for a maximum amount not exceeding Rs. 210 Crores.
Who will manage the upcoming Rights Issue for Arvaya Healthcare?
A Rights Issue Committee comprising Mr. Kaushal Uttam Shah, Mr. Salil Shetty, and Mr. Rahul Ravindra Mayur has been constituted to manage the Rights Issue.
Questions based on this BSE filing only. For information purposes.